Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Belle Health LLC dba Belle
WARNING LETTER
•Belle Health LLC dba Belle•December 31, 2025

Belle Health LLC dba Belle – FDA Warning Letter, Dec 31, 2025

Record Details

The FDA issued a Warning Letter to Belle Health LLC dba Belle on February 20, 2026, after reviewing their website, joinbelle.com, in December 2025. The agency found that Belle's website offers compounded semaglutide and tirzepatide drug products, which are misbranded. The main violation stems from false or misleading claims on the product labels displayed online, where "Belle" is identified as the compounder, despite Belle not being the actual compounding entity.

This misrepresentation violates sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA), which stipulate that drug labeling and compounded drug advertising must not be false or misleading. Introducing these misbranded products into interstate commerce is a prohibited act under section 301(a) of the FDCA.

Belle Health LLC is required to provide a written response to the FDA within fifteen working days, detailing immediate actions taken to address these violations and prevent recurrence. This includes identifying the actual compounders of the products, providing representative labeling samples, and modifying or removing any other false or misleading claims on their website. Failure to comply could result in further legal action, including product seizure and injunction.

Company
Belle Health LLC dba Belle
Inspection date
December 31, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Matthew J. Lash (Acting Director)
View Company Profile

ID · 82bebe97-50c2-465c-be98-fc7c137a33e9

Violation Codes10
21 U.S.C. 321(p)21 U.S.C. 331(c)FD&C Act 503AFD&C Act 201(g)21 CFR 201.61(a)FD&C Act 503B(A)(10)(A)(i)FD&C Act 301(c)21 U.S.C. 352(a)FD&C Act 503(b)FD&C Act 201(p)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Belle Health LLC dba Belle
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.